## Extended Point Prevalence Audit Survey (PPAS)

Results for Moldova





This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003589.





















Version 01 2

## **Extended PPAS Moldova**

## **General information**

- Country: MOLDOVA
- Registration period: 16 April 2020 to 05 July 2020
- Total number of patient consultations: 239

## Overall remarks on Moldovan data

- 24,3% of patients were seen at the practice, 34,7% were contacted by phone and 40,6% were contacted by video
- Masks and gloves were used in all consultations
- 57,3% of the patients had mild disease
- In 81,6% of the patients a COVID test was ordered
- In 58,2% of patients the working diagnosis was COVID
- In those with an empirical diagnosis of COVID, only 0,7% did get an antibiotic
- 17,2% of patients was referred to hospital



Consultation (N=239)							
	Practice	24.3%					
Consultation at	Home	0.8 %					
	Protective measures: yes			apron/body protection		98.3%*	
		98.3 %		face, nose/mouth protection	100	100%	
				safety glasses gloves		100% 100%	
	Telephone	34.7%					
	Video/skype	40.2%					
				Result:			
Has patient	Yes	30.1%		Positive		66.7%*	
already been tested for COVID?		30.1%		Negative		33.3%	
				Unknown		0.0%	
Patient characteri	No stics	69.9%					
	Median (IQR)	39 (28-55)					
Age	Yes	35.6%	chronic respiratory				
Comorbidity			cond	ition		40.0%* 21.2%	
			diabetes cardiovascular disease			72.9%	
Measured:			caraiovasculai uisease			12.970	
Fever	Yes	95.0%"	Temp>=38 or <36		5.3%*		
O <sub>2</sub>	Yes	98.3%"		Saturation <96%		1.5%*	
Resp. rate	Yes	98.3%"	Resp	Resp. rate >20 or <12		9.2%^	
Signs and sympto	ms						
Rhinitis	Yes	33.5%					
Sore throat	Yes	88.7%					
Cough	Yes	49.4%	(dysp	of breath onoea)	8.8%#		
			abnormal auscultation		23.3%"	23.3%"	
			(pleuritic) chest pain		5.0%#		
				tachypnoea		1.7%#	
Comparel	Yes 76.2% headache		ache	59.0%#			
General symptoms			altered mental 0.4% status				

			fatigue diarrhoea		51.0%		
					5.0%		
	Mild	57.3%					
Overall illness severity	Moderate	41.0%					
	Severe	1.7%					
Additional diagnostic tests	Yes			CRP		13.3%*	
				CRP Median (IQR)	-		
		66.1%		COVID-19 test		81.6%	
				Total white blood cell count	4	41.1%	
				Chest X-ray	22.8%		
	viral (no COVID-19)				35.1%		
Suspected aetiology	COVID-19				56.5%		
	bacterial				11.3%		
	allergic				0%		
	not clear		7.1%				
	acute pharyngitis/tonsillitis/abscess 27.2%						
	laryngitis/laryngotracheitis influenza-like-illness			0.0%			
	bronchiolitis	0.4%					
	acute bronchitis	1.7%					
	CAP	1.7%					
	exacerbation COPD/asthma			5.0%			
Initial working	upper RTI			18.8%			
diagnosis				58.2%			
				Contacted public health authorities?		100%*	
				Would you recommend testing?		Yes: 100%	
GP provided	advice for home isolation	77.0%		how many days? Median		ı (5-14)	
	advice for symptomatic treatment	88.3%	(ICQ)				
	a scheduled follow-up visit/call	82.4%					

	prescribed medication	33.9%	inhaled m	edication	16.3%#		
			antibiotic		11.3%		
			antiviral medication		2.1%		
			antihistamines		13.4%		
	advice for family	83.7%	home isol	ation	49.0%#		
	members	03.770	social dist	ancing	81.6%		
			extra hand	dwashing	95.4%#		
			sneezing i	n sleeve	95.4%		
	preventive		social distancing		95.0%		
	measures for patient	95.8%	nose/mouth protection		94.6%		
			staying in separate room		54.8%		
	where to find reliable information	52.7%					
GP prescribed	Antibiotics if working diagnose was COVID- Yes 0.7%						
Confidence that	Very confident	13.0%	Very confident		4.3% <sup>\$</sup>		
provided	Confident	66.5%	Confident		64.0% <sup>\$</sup>		
advice/treatmen	Moderately	20.1%	Moderately		30.9%\$		
t will benefit this	Unconfident	0.4%	Unconfide	nt	0.7% <sup>\$</sup>		
patient	Very unconfident	0.0%	Very unco	nfident	0.0%\$		
	Referral to hospital	17.2%					
	Advise contact/refer to COVID-specific authority	59.0%					

<sup>\*</sup> percentage from yes " percentage from F2F contact # percentage from total (n=240) ^ percentage from adults and yes \$ if suspected etiology is COVID-19

